Report Detail

Request for Sample of this report

Pharma & Healthcare Global Drugs for Herpes Labialis (Oral Herpes) Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM2867237
    • |
  • 17 April, 2023
    • |
  • Global
    • |
  • 92 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
According to our (Global Info Research) latest study, the global Drugs for Herpes Labialis (Oral Herpes) market size was valued at USD 2529.2 million in 2022 and is forecast to a readjusted size of USD 3485.7 million by 2029 with a CAGR of 4.7% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
This report is a detailed and comprehensive analysis for global Drugs for Herpes Labialis (Oral Herpes) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Drugs for Herpes Labialis (Oral Herpes) market size and forecasts, in consumption value ($ Million), 2018-2029
Global Drugs for Herpes Labialis (Oral Herpes) market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Drugs for Herpes Labialis (Oral Herpes) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Drugs for Herpes Labialis (Oral Herpes) market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for Herpes Labialis (Oral Herpes)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for Herpes Labialis (Oral Herpes) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Novartis, Teva, Mylan and Cadila, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Drugs for Herpes Labialis (Oral Herpes) market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Market segment by Application
External Use
Oral
Injection
Market segment by players, this report covers
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Drugs for Herpes Labialis (Oral Herpes) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Drugs for Herpes Labialis (Oral Herpes), with revenue, gross margin and global market share of Drugs for Herpes Labialis (Oral Herpes) from 2018 to 2023.
Chapter 3, the Drugs for Herpes Labialis (Oral Herpes) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Drugs for Herpes Labialis (Oral Herpes) market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Drugs for Herpes Labialis (Oral Herpes).
Chapter 13, to describe Drugs for Herpes Labialis (Oral Herpes) research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Drugs for Herpes Labialis (Oral Herpes)
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Drugs for Herpes Labialis (Oral Herpes) by Type
    • 1.3.1 Overview: Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Value Market Share by Type in 2022
    • 1.3.3 Aciclovir
    • 1.3.4 Valacyclovir
    • 1.3.5 Famciclovir
    • 1.3.6 Docosanol
    • 1.3.7 Other
  • 1.4 Global Drugs for Herpes Labialis (Oral Herpes) Market by Application
    • 1.4.1 Overview: Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 External Use
    • 1.4.3 Oral
    • 1.4.4 Injection
  • 1.5 Global Drugs for Herpes Labialis (Oral Herpes) Market Size & Forecast
  • 1.6 Global Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast by Region
    • 1.6.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region, (2018-2029)
    • 1.6.3 North America Drugs for Herpes Labialis (Oral Herpes) Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size and Prospect (2018-2029)
    • 1.6.6 South America Drugs for Herpes Labialis (Oral Herpes) Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 GSK
    • 2.1.1 GSK Details
    • 2.1.2 GSK Major Business
    • 2.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.1.4 GSK Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 GSK Recent Developments and Future Plans
  • 2.2 Novartis
    • 2.2.1 Novartis Details
    • 2.2.2 Novartis Major Business
    • 2.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.2.4 Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Novartis Recent Developments and Future Plans
  • 2.3 Teva
    • 2.3.1 Teva Details
    • 2.3.2 Teva Major Business
    • 2.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.3.4 Teva Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Teva Recent Developments and Future Plans
  • 2.4 Mylan
    • 2.4.1 Mylan Details
    • 2.4.2 Mylan Major Business
    • 2.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.4.4 Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Mylan Recent Developments and Future Plans
  • 2.5 Cadila
    • 2.5.1 Cadila Details
    • 2.5.2 Cadila Major Business
    • 2.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.5.4 Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Cadila Recent Developments and Future Plans
  • 2.6 Apotex
    • 2.6.1 Apotex Details
    • 2.6.2 Apotex Major Business
    • 2.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.6.4 Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Apotex Recent Developments and Future Plans
  • 2.7 Daewoong Pharmaceutical
    • 2.7.1 Daewoong Pharmaceutical Details
    • 2.7.2 Daewoong Pharmaceutical Major Business
    • 2.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.7.4 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Daewoong Pharmaceutical Recent Developments and Future Plans
  • 2.8 Livzon
    • 2.8.1 Livzon Details
    • 2.8.2 Livzon Major Business
    • 2.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.8.4 Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Livzon Recent Developments and Future Plans
  • 2.9 Luoxin
    • 2.9.1 Luoxin Details
    • 2.9.2 Luoxin Major Business
    • 2.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.9.4 Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Luoxin Recent Developments and Future Plans
  • 2.10 Med shine
    • 2.10.1 Med shine Details
    • 2.10.2 Med shine Major Business
    • 2.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.10.4 Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Med shine Recent Developments and Future Plans
  • 2.11 Bayer (Campho Phenique)
    • 2.11.1 Bayer (Campho Phenique) Details
    • 2.11.2 Bayer (Campho Phenique) Major Business
    • 2.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.11.4 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Bayer (Campho Phenique) Recent Developments and Future Plans
  • 2.12 Blistex
    • 2.12.1 Blistex Details
    • 2.12.2 Blistex Major Business
    • 2.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.12.4 Blistex Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Blistex Recent Developments and Future Plans
  • 2.13 Kelun
    • 2.13.1 Kelun Details
    • 2.13.2 Kelun Major Business
    • 2.13.3 Kelun Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.13.4 Kelun Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Kelun Recent Developments and Future Plans
  • 2.14 Hikma
    • 2.14.1 Hikma Details
    • 2.14.2 Hikma Major Business
    • 2.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.14.4 Hikma Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Hikma Recent Developments and Future Plans
  • 2.15 Haiwang
    • 2.15.1 Haiwang Details
    • 2.15.2 Haiwang Major Business
    • 2.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.15.4 Haiwang Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 Haiwang Recent Developments and Future Plans
  • 2.16 Carmex
    • 2.16.1 Carmex Details
    • 2.16.2 Carmex Major Business
    • 2.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.16.4 Carmex Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 Carmex Recent Developments and Future Plans
  • 2.17 Cipher
    • 2.17.1 Cipher Details
    • 2.17.2 Cipher Major Business
    • 2.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Product and Solutions
    • 2.17.4 Cipher Drugs for Herpes Labialis (Oral Herpes) Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 Cipher Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Drugs for Herpes Labialis (Oral Herpes) by Company Revenue
    • 3.2.2 Top 3 Drugs for Herpes Labialis (Oral Herpes) Players Market Share in 2022
    • 3.2.3 Top 6 Drugs for Herpes Labialis (Oral Herpes) Players Market Share in 2022
  • 3.3 Drugs for Herpes Labialis (Oral Herpes) Market: Overall Company Footprint Analysis
    • 3.3.1 Drugs for Herpes Labialis (Oral Herpes) Market: Region Footprint
    • 3.3.2 Drugs for Herpes Labialis (Oral Herpes) Market: Company Product Type Footprint
    • 3.3.3 Drugs for Herpes Labialis (Oral Herpes) Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Type (2018-2029)
  • 6.2 North America Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Application (2018-2029)
  • 6.3 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country
    • 6.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Country (2018-2029)
    • 6.3.2 United States Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Type (2018-2029)
  • 7.2 Europe Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Application (2018-2029)
  • 7.3 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country
    • 7.3.1 Europe Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 7.3.3 France Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Region
    • 8.3.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Region (2018-2029)
    • 8.3.2 China Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 8.3.5 India Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Type (2018-2029)
  • 9.2 South America Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Application (2018-2029)
  • 9.3 South America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country
    • 9.3.1 South America Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country
    • 10.3.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Drugs for Herpes Labialis (Oral Herpes) Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Drugs for Herpes Labialis (Oral Herpes) Market Drivers
  • 11.2 Drugs for Herpes Labialis (Oral Herpes) Market Restraints
  • 11.3 Drugs for Herpes Labialis (Oral Herpes) Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Drugs for Herpes Labialis (Oral Herpes) Industry Chain
  • 12.2 Drugs for Herpes Labialis (Oral Herpes) Upstream Analysis
  • 12.3 Drugs for Herpes Labialis (Oral Herpes) Midstream Analysis
  • 12.4 Drugs for Herpes Labialis (Oral Herpes) Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Drugs for Herpes Labialis (Oral Herpes) . Industry analysis & Market Report on Drugs for Herpes Labialis (Oral Herpes) is a syndicated market report, published as Global Drugs for Herpes Labialis (Oral Herpes) Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Drugs for Herpes Labialis (Oral Herpes) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,797.92
    		4,196.88
    		5,595.84
    		3,253.80
    		4,880.70
    		6,507.60
    		538,390.80
    		807,586.20
    		1,076,781.60
    		289,988.40
    		434,982.60
    		579,976.80
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo